Home · Stock · IONS

IONS Ionis Pharmaceuticals Inc

Which ETFs hold IONS? Ionis Pharmaceuticals Inc is held by 1 fund tracked by ETFpeek.

Held by 1 fund todayData as of 9 Oct 2026
HealthcareBiotechnology
$43.30
-38.1% 1y
$42.6352-week range$86.74
Market cap
$7.2B
3-month
-25.7%
CEO
Dr. Brett P. Monia Ph.D.
Revenue · last 4 qtrs (-40.7% YoY)

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Provider

Currently Held By

ARK
ARKG
ARK Genomic Revolution ETF
Weight in fund1.84%
Shares held872,018
Market value$37.8M
View fund →
Not held by the selected provider.
last 90 days
Net flow (90d):+$1.1M (4 without value)·6 BUY / 0 SELL·score ≥ 40
DatePersonActionPlanSharesValueScore i
31 Jul 2026
Michael R Hayden
Director / Other
BUYDiscretionary5,000$258K80
30 Jul 2026
Michael R Hayden
Director / Other
BUYDiscretionary15,000$801K100
Net flow (90d):+$1.1M (4 without value)·6 BUY / 0 SELL·showing all trades
DatePersonActionPlanSharesValueScore i
31 Jul 2026
Michael R Hayden
Director / Other
BUYDiscretionary5,000$258K80
30 Jul 2026
Michael R Hayden
Director / Other
BUYDiscretionary15,000$801K100
15 Jul 2026
Peter N Reikes
Director / Other
BUYVested (RSU)3,399—30
15 Jul 2026
Ludwig Hantson
Director / Other
BUYVested (RSU)3,399—30
15 Jul 2026
Joan E Herman
Director / Other
BUYOption Exercise5,220—30
15 Jul 2026
Spencer R Berthelsen
Director / Other
BUYOption Exercise5,220—30
Data: Finnhub (SEC Form 4 filings) · Score: ETFpeek heuristic
9 trades
DateFundDirectionShares Changed% Δ ETF i% Δ Position i
22 Sep 2026ARKGBUYAdded+100,246+0.21%11.35%
15 Sep 2026ARKGBUYAdded+166,580+0.33%22.30%
20 Aug 2026ARKGBUYAdded+18,484-0.08%3.16%
19 Aug 2026ARKGBUYAdded+26,246+0.15%4.76%
18 Aug 2026ARKGBUYAdded+6,839+0.05%1.30%
15 Jul 2026ARKGBUYAdded+49,004+0.10%9.31%
14 Jul 2026ARKGBUYAdded+66,278+0.22%13.85%
13 Jul 2026ARKGBUYAdded+28,035+0.01%6.79%
10 Jul 2026ARKGBUYAdded+105,364+0.03%27.35%
No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal.

More stocks in these funds